Lymphoma Patients' vaccine response under scrutiny

NCT ID NCT05050461

Terminated Knowledge-focused Sponsor: Versailles Hospital Source: ClinicalTrials.gov ↗

First seen Jun 27, 2026 · Last updated Jun 27, 2026

Summary

This study looked at how well the COVID-19 vaccine works in adults with B-cell non-Hodgkin lymphoma, especially those who received a common treatment called anti-CD20 monoclonal antibodies in the past year. Researchers compared antibody and T-cell responses between treated and untreated patients to understand if prior therapy weakens vaccine protection. The goal was to guide future vaccine and treatment recommendations for this vulnerable group.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for NON-HODGKIN LYMPHOMA,B CELL are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Conditions

The condition(s) this trial relates to.

B-cell non-Hodgkin lymphoma

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

NON-HODGKIN LYMPHOMA,B CELL VACCINATION FAILURE

Contacts and locations

Locations

André Mignot -Versailles Hospital, Hemato-oncology unit

Le Chesnay, Île-de-France Region, 78150, France
Emile Muller Hospital, Hematology unit

Mulhouse, 68100, France
Hospitals of Brabois, Hematology unit

Vandœuvre-lès-Nancy, 54500, France
Institut of Cancerology Strasbourg Europe (ICANS), Hematology deparment

Strasbourg, 67000, France
Pitié Salpêtrière Hospital, Hematology unit

Paris, Île-de-France Region, 75013, France
Saint Antoine Hospital, Hematology unit

Paris, Île-de-France Region, 75012, France
saint Louis Hospital, Hemato-oncology unit

Paris, Île-de-France Region, 75010, France

More trials for these conditions

Other studies related to the condition(s) this trial covers.